Literature DB >> 21873342

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.

Gerrit Frommeyer1, Peter Milberg, Patricia Witte, Jörg Stypmann, Matthias Koopmann, Martin Lücke, Nani Osada, Günter Breithardt, Michael Fehr, Lars Eckardt.   

Abstract

AIMS: Life-threatening arrhythmias are a major problem in chronic heart failure (CHF). The aim of the present study was to investigate the mechanism underlying the low proarrhythmic potential of amiodarone in a model of pacing-induced heart failure. METHODS AND
RESULTS: Heart failure was induced in 35 female rabbits by rapid ventricular pacing, resulting in a significant decrease of ejection fraction. Thirty-four rabbits were sham-operated. In 17 of 35 CHF-rabbits and 20 of 34 'sham'-rabbits, amiodarone (50 mg/kg/day) was fed for 6 weeks. Eight monophasic action potentials and a simultaneously recorded 12-lead electrocardiogram showed prolongation of QT-interval and action potential duration (APD(90)) in all failing hearts (P< 0.05). Amiodarone pre-treatment led to a prolongation of APD(90) (+19 ms) as compared with sham-controlled hearts but showed only a marginal effect on APD(90) in failing hearts. Infusion of sotalol (50-100 µM) led to a significant prolongation of APD(90) in sham and a further prolongation of APD(90) in failing hearts [+55 ms (50 µM); +70 ms (100 µM); P< 0.01 as compared with sham hearts]. Sotalol led to a triangular action potential configuration in sham and failing hearts, whereas amiodarone did not cause triangularization but caused a rapid phase-III repolarization. Moreover, amiodarone did not increase dispersion of repolarization either in sham or in failing hearts. Infusion of sotalol led to a significant increase in dispersion of repolarization in sham (+29 ms) and a further increase in failing hearts (+67 ms; P< 0.05).
CONCLUSION: Chronic amiodarone results in a rapid phase-III-repolarization and does not increase dispersion of repolarization. These electrophysiological findings are present in healthy hearts and are preserved in heart failure. This contributes to the low proarrhythmic potential of amiodarone in heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873342     DOI: 10.1093/eurjhf/hfr107

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

1.  Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.

Authors:  P Milberg; M Fink; C Pott; G Frommeyer; J Biertz; N Osada; J Stypmann; G Mönnig; M Koopmann; G Breithardt; L Eckardt
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.

Authors:  Gerrit Frommeyer; Henning von der Ahe; Benedict Brücher; Dirk G Dechering; Philipp S Lange; Florian Reinke; Kristina Wasmer; Julia Köbe; Christian Pott; Gerold Mönnig; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-12       Impact factor: 3.000

3.  Application of the Bogossian formula for evaluation of the QT interval in pacemaker patients with stimulated left bundle branch block.

Authors:  K F Weipert; H Bogossian; P Conzen; G Frommeyer; C Gemein; I Helmig; R Chasan; L Eckardt; M Seyfarth; B Lemke; M Zarse; C W Hamm; J Schmitt; D Erkapic
Journal:  Clin Res Cardiol       Date:  2018-05-11       Impact factor: 5.460

Review 4.  [Ventricular tachyarrhythmia as a side effect of pharmacotherapy].

Authors:  Thomas Demming; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-09

5.  Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?

Authors:  Thom R G Stams; Vincent J A Bourgonje; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  Monophasic action potential amplitude for substrate mapping.

Authors:  Ikeotunye Royal Chinyere; Mathew Hutchinson; Talal Moukabary; Jordan Lancaster; Steven Goldman; Elizabeth Juneman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-26       Impact factor: 4.733

7.  The ECG in cardiovascular-relevant animal models of electrophysiology.

Authors:  Sven Kaese; Gerrit Frommeyer; Sander Verheule; Gunther van Loon; Josef Gehrmann; Günter Breithardt; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-06-06

Review 8.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 9.  An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure.

Authors:  Valentina Buda; Andreea Prelipcean; Dragos Cozma; Dana Emilia Man; Simona Negres; Alexandra Scurtu; Maria Suciu; Minodora Andor; Corina Danciu; Simina Crisan; Cristina Adriana Dehelean; Lucian Petrescu; Ciprian Rachieru
Journal:  J Clin Med       Date:  2022-04-04       Impact factor: 4.241

10.  Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms!

Authors:  Lars S Maier
Journal:  Eur J Heart Fail       Date:  2012-10-30       Impact factor: 15.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.